Substance Use Disorder

Approximately 7.6% of men and 4.1% of women aged 18 and older suffer from AUD, but national surveys consistently demonstrate low utilization of treatments.

Is cannabis’ effect on schizophrenia being downplayed?

A coalition of 240 organizations came together to urge Congress to pass legislation to fight the opioid crisis.

Scare tactics don’t work. But scientific education might. Here are tips for talking with teenaged patients about keeping themselves and their friends safe.

Chronic adolescent exposure to THC and cannabis could lead to adverse mental health outcomes and impacted brain functioning.

How can psychiatrists improve substance use treatment for Black and pediatric patients?

At the Annual Psychiatric Times World CME Conference, an all-star lineup of presenters will share their latest research. Check out this preview of the full agenda.

The American Medical Association is urging policymakers to act now to prevent further opioid overdose deaths.

A vaccine that prevents oxycodone from entering the brain? This might be the safe, long-lasting, cost-effective solution for opioid use disorders.

Decades after September 11, 2001, many first responders still live with PTSD. Will the same be true of physicians who saw the worst of the pandemic?

What can be done to help patients turn painful memories into opportunities for posttraumatic growth?

Are benzodiazepine prescriptions contributing to the opioid overdose epidemic?

In this journal club, a medical student and an addiction psychiatrist review a thematic analysis of successful prevention efforts in states with declining rates of opioid-related overdose deaths.

A patient presents with multiple substance use disorders super-imposed on mood and anxiety disorders. Where does a clinician even begin?

Manufactured fentanyl is a major cause of overdoses for opioids and nonopiods. Can a vaccine immunize against overdose?

After the largest increase in overdose deaths in 50 years, the American Psychiatric Association sends out the call for improved substance use care.

Novel digital therapy modia will be evaluated in combination with sublingual buprenorphine/naloxone background therapy to see whether it is superior in reducing opioid use.

The potential role of eye movement desensitization and reprocessing.

Yes, we need better crisis management, but what we really need is better crisis prevention.

Adial’s AD04 for the treatment of alcohol use disorder received a Notice of Allowance from the US Patent and Trademark Office.

The Drug Policy Reform Act, introduced today, intends to decriminalize drug use and possession, providing health-centered approaches and rehabilitation instead.

How can understanding the opioid crisis in Canada inform strategies in the United States?

Healthy lungs are at risk—what can you do as a clinician to help patients quit vaping?